Expression And Clinical Significance Of Metastin And MMP-9 In Endometrial Adenocarcinoma

Objective:This article aims to research the expression of Metastin and MMP-9 in endometrial adenocarcinoma, atypical hyperplasia endometrium and normal endometrium,and explore the role it plays in the occurrence and development of endometrial adenocarcinoma, and to provide theoretical basis for diagnosis judgment of malignancy degree, and prognosis in endometrial adenocarcinoma, and to provide new theoretical basis for gene therapy of endometrial adenocarcinoma.Methods:35 specimens of endometrial adenocarcinoma which are collected randomly are used as experimental group, and 20 atypical hyperplasia endometrium specimens of patients and 22 normal endometrium specimens are used as the control group. For the purpose of testing the expression of Metastin and MMP-9 in normal endometrium, atypical hyperplasia endometrium and endometrial adenocarcinoma, and of analyzing the relationship between the expression of Metastin and MMP-9 and various clinic-pathology parameters, and of analyzing the relationship between Metastin and MMP-9, immunohistochemistry is adopted.In order to make statistical analysis, SPSS170.0 statistical software package is used.Results: Comparing between the three groups, the difference is significant(P<0.05).1. The positive expression rates of Metastin in normal endometrium, atypical hyperplasia endometrium and endometrial carcinoma respectively are 86.4%, 90% and 37.1%.Comparing between the three groups, the difference is significant(P<0.05).There is no significant difference between the positive expression rates of Metastin in endometrial carcinoma and atypical hyperplasia endometrium (χ2=0, P>0.05). The positive expression of Metastin in normal endometrium and atypical hyperplasia endometrium is significantly different from that in endometrial carcinoma (P<0.05).2. The positive expression rates of MMP-9 in normal endometrium, atypical hyperplasia endometrium and endometrial adenocarcinoma are 13.6%, 30% and 62.9%. Comparing between the three groups, the difference is significant(P<0.05).The positive expression rates of MMP-9 in endometrial carcinoma is no significant difference from atypical hyperplasia endometrium(χ2=0.836,P>0.05). They respectively compare with endometrial adenocarcinoma, the difference is very significant, P<0.05.3. The positive expression rate of Metastin in the Well-differentiated endometrial adenocarcinoma is 56.3%,the same time, the positive expression rate of Metastin in the group of moderately and poorly differentiated is 21.1%,compare among the two groups, there is significant difference (P<0.05).In the Well-differentiated endometrial adenocarcinoma, moderately and poorly differentiated endometrial adenocarcinoma, the positive expression rates of MMP-9 are 50% and 73.7%, there is no significant difference (P>0.05).4. The positive expression rate of Metastin in the muscular layer infiltration depth<1/2 of endometrial adenocarcinoma groups is 83.3%, and in the muscular layer infiltration depth≥1/2 groups is 22.2%, by statistical comparison, the difference is significant (P<0.05). The positive expression rate of MMP-9 in the two groups are separately 30.8% and 66.7%,the statistical difference is not significant (P>0.05)5. None is positive expression of Metastin in the with lymph node metastasis group, whereas the positive expression rate of Metastin in without lymph node metastasis group is 46.4%, comparing between them the difference is significant (P<0.05).The positive expression rate of MMP-9 in with and without lymph node metastasis of endometrial adenocarcinoma are 85.7% and 57.1%, compared between them there is no significant difference (P>0.05).6. In the surgical-pathological staging I group, II and III group of endometrial adenocarcinoma, the positive expression rate of Metastin respectively are 54.5% and 7.7%, there is significant difference between them (P<0.05). In surgical-pathological staging I group, II and III group of endometrial adenocarcinoma, the positive expression rates of MMP-9 respectively are 45.5% and 92.2%, there is significant statistics difference between them (P<0.05).7. The positive expression rate of Metastin and MMP-9 shows negative relationship(γ=-0.388,P<0.05).Conclusion:1.Lower expression of Metastin may promote malignant progress of endometrial adenocarcinoma.2. Higher expression of MMP-9 may contribute to occurrence and development in endometrial adenocarcinoma. 3. Lower expression of Metastin in endometrial adenocarcinoma may indicate more malignant and easier to relapse.4. Higher expression of MMP-9 in endometrial adenocarcinoma may indicate more aggressive and poor prognosis.5. In endometrial adenocarcinoma tissues,the positive expression of Metastin and MMP-9 shows negative correlation. They are antagonistic effect on occurrence and development of endometrial adenocarcinoma.6. Monitoring the expression of Metastin and MMP-9 in endometrial adenocarcinoma can be used to determine the malignant tumor degree and prognosis.